Cargando…

Progress in Elucidating Potential Markers and Mechanisms of Rapid Protection Conferred by the VSV-Vectored Ebola Virus Vaccine

Research progress over the past 20 years has yielded several experimental Ebola virus (EBOV) vaccine candidates, which were shown to be effective in nonhuman primates when given 28 days before a lethal challenge. Of these, the vesicular stomatitis virus (VSV)-vectored vaccine against EBOV (VSV-EBOV)...

Descripción completa

Detalles Bibliográficos
Autor principal:	Wong, Gary
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2019
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6635535/ https://www.ncbi.nlm.nih.gov/pubmed/31311887 http://dx.doi.org/10.1128/mBio.01597-19

Ejemplares similares

Safety of Recombinant VSV–Ebola Virus Vaccine Vector in Pigs
por: de Wit, Emmie, et al.
Publicado: (2015)

Human Transcriptomic Response to the VSV-Vectored Ebola Vaccine
por: Santoro, Francesco, et al.
Publicado: (2021)

Detectable Vesicular Stomatitis Virus (VSV)–Specific Humoral and Cellular Immune Responses Following VSV–Ebola Virus Vaccination in Humans
por: Poetsch, Joseph H, et al.
Publicado: (2019)

A recombinant VSV-vectored vaccine rapidly protects nonhuman primates against lethal Nipah virus disease
por: Foster, Stephanie L., et al.
Publicado: (2022)

Single low-dose VSV-EBOV vaccination protects cynomolgus macaques from lethal Ebola challenge
por: Marzi, Andrea, et al.
Publicado: (2019)

Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!)
por: Henao-Restrepo, Ana Maria, et al.
Publicado: (2017)

Can Ebola virus become endemic in the human population?
por: Wong, Gary, et al.
Publicado: (2015)

Virus-Vectored Ebola Vaccines
por: Dolzhikova, I.V., et al.
Publicado: (2017)

Antiviral Innate Responses Induced by VSV-EBOV Vaccination Contribute to Rapid Protection
por: Menicucci, Andrea R., et al.
Publicado: (2019)

Single Dose of a VSV-Based Vaccine Rapidly Protects Macaques From Marburg Virus Disease
por: Marzi, Andrea, et al.
Publicado: (2021)

From discovery to delivery: public sector development of the rVSV-ZEBOV Ebola vaccine
por: Herder, Matthew, et al.
Publicado: (2020)

Pseudotyping of VSV with Ebola virus glycoprotein is superior to HIV-1 for the assessment of neutralising antibodies
por: Steeds, Kimberley, et al.
Publicado: (2020)

Postexposure Prophylaxis With rVSV-ZEBOV Following Exposure to a Patient With Ebola Virus Disease Relapse in the United Kingdom: An Operational, Safety, and Immunogenicity Report
por: Davis, Chris, et al.
Publicado: (2019)

Optimal Expression, Function, and Immunogenicity of an HIV-1 Vaccine Derived from the Approved Ebola Vaccine, rVSV-ZEBOV
por: Azizi, Hiva, et al.
Publicado: (2023)

Circulating follicular T helper cells and cytokine profile in humans following vaccination with the rVSV-ZEBOV Ebola vaccine
por: Farooq, Fouzia, et al.
Publicado: (2016)

A VSV-based Zika virus vaccine protects mice from lethal challenge
por: Emanuel, Jackson, et al.
Publicado: (2018)

Rapid protection of nonhuman primates against Marburg virus disease using a single low-dose VSV-based vaccine
por: O'Donnell, Kyle L., et al.
Publicado: (2023)

Spray dried VSV-vectored vaccine is thermally stable and immunologically active in vivo
por: Toniolo, Steven P., et al.
Publicado: (2020)

Environmental Risk Assessment for rVSVΔG-ZEBOV-GP, a Genetically Modified Live Vaccine for Ebola Virus Disease
por: Tell, Joan G., et al.
Publicado: (2020)

Ring vaccination with rVSV-ZEBOV under expanded access in response to an outbreak of Ebola virus disease in Guinea, 2016: an operational and vaccine safety report
por: Gsell, Pierre-Stéphane, et al.
Publicado: (2017)

Development and Applications of VSV Vectors Based on Cell Tropism
por: Tani, Hideki, et al.
Publicado: (2012)

Pregnancy Outcomes among Women Receiving rVSVΔ-ZEBOV-GP Ebola Vaccine during the Sierra Leone Trial to Introduce a Vaccine against Ebola
por: Legardy-Williams, Jennifer K., et al.
Publicado: (2020)

The viral vector vaccine VSV-GP boosts immune response upon repeated applications
por: Tober, R, et al.
Publicado: (2012)

Optimizing expression of functional HIV envelopes in rVSV-ΔG vaccine vectors
por: Wright, KJ, et al.
Publicado: (2012)

Safety and immunogenicity of GamEvac-Combi, a heterologous VSV- and Ad5-vectored Ebola vaccine: An open phase I/II trial in healthy adults in Russia
por: Dolzhikova, I. V., et al.
Publicado: (2017)

Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine
por: Kapadia, Sagar U., et al.
Publicado: (2005)

Ethics and execution of developing a 2nd wave COVID vaccine – Our interim phase I/II VSV-SARS-CoV2 vaccine experience
por: Levin, Yotam, et al.
Publicado: (2021)

Protection Against Marburg Virus Using a Recombinant VSV-Vaccine Depends on T and B Cell Activation
por: Marzi, Andrea, et al.
Publicado: (2019)

The rVSV-EBOV vaccine provides limited cross-protection against Sudan virus in guinea pigs
por: Cao, Wenguang, et al.
Publicado: (2023)

Effects of adjuvants in a rabies-vectored Ebola virus vaccine on protection from surrogate challenge
por: Yankowski, Catherine, et al.
Publicado: (2023)

Recombinant Sudan virus and evaluation of humoral cross-reactivity between Ebola and Sudan virus glycoproteins after infection or rVSV-ΔG-ZEBOV-GP vaccination
por: Kainulainen, Markus H., et al.
Publicado: (2023)

YF17D-vectored Ebola vaccine candidate protects mice against lethal surrogate Ebola and yellow fever virus challenge
por: Lemmens, Viktor, et al.
Publicado: (2023)

Development of candidate HIV vaccines using VSV vectors to express membrane-anchored MPER immunogen
por: Yuan, M, et al.
Publicado: (2012)

A Replicating Cytomegalovirus-Based Vaccine Encoding a Single Ebola Virus Nucleoprotein CTL Epitope Confers Protection against Ebola Virus
por: Tsuda, Yoshimi, et al.
Publicado: (2011)

Mucosal Immunization of Cynomolgus Macaques with the VSVΔG/ZEBOVGP Vaccine Stimulates Strong Ebola GP-Specific Immune Responses
por: Qiu, Xiangguo, et al.
Publicado: (2009)

Systems Vaccinology Identifies an Early Innate Immune Signature as a Correlate of Antibody Responses to the Ebola Vaccine rVSV-ZEBOV
por: Rechtien, Anne, et al.
Publicado: (2017)

Immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccination in exposed and potentially exposed persons in the Democratic Republic of the Congo
por: Hoff, Nicole A., et al.
Publicado: (2022)

Implications of Ebola virus disease on wildlife conservation in Nigeria
por: Egbetade, Adeniyi Olugbenga, et al.
Publicado: (2015)

Repurposing the oncolytic virus VSV∆51M as a COVID-19 vaccine
por: Alkayyal, Almohanad A., et al.
Publicado: (2023)

To B or Not to B: Mechanisms of Protection Conferred by rVSV-EBOV-GP and the Roles of Innate and Adaptive Immunity
por: Pinski, Amanda N., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_9a0dk4utj69c2i866lg4usl989